A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.
Sign Up to like & getrecommendations! Published in 2017 at "European journal of cancer"
DOI: 10.1016/j.ejca.2017.10.016
Abstract: PURPOSE Dysregulated MET signalling is implicated in oncogenesis. The safety and preliminary efficacy of a highly selective MET kinase inhibitor (SAR125844) was investigated in patients with advanced solid tumours and MET dysregulation. METHODS This was… read more here.
Keywords: met amplification; kinase inhibitor; selective met; patients advanced ... See more keywords
Selective MET Kinase Inhibition in MET-Dependent Glioma Models Alters Gene Expression and Induces Tumor Plasticity
Sign Up to like & getrecommendations! Published in 2017 at "Molecular Cancer Research"
DOI: 10.1158/1541-7786.mcr-17-0177
Abstract: The receptor tyrosine kinase (RTK) MET represents a promising tumor target in a subset of glioblastomas. Most RTK inhibitors available in the clinic today, including those inhibiting MET, affect multiple targets simultaneously. Previously, it was… read more here.
Keywords: kinase inhibition; inhibition; selective met; compound ... See more keywords